Search

Your search keyword '"M. Sorschag"' showing total 3 results
Start Over Author "M. Sorschag"
3 results on '"M. Sorschag"'

1. Abstracts of the 33rd International Austrian Winter Symposium

Author

K. Binzel, A. Adelaja, C. L. Wright, D. Scharre, J. Zhang, M. V. Knopp, E. J. Teoh, D. Bottomley, A. Scarsbrook, H. Payne, A. Afaq, J. Bomanji, N. van As, S. Chua, P. Hoskin, A. Chambers, G. J. Cook, V. S. Warbey, A. Chau, P. Ward, M. P. Miller, D. J. Stevens, L. Wilson, F. V. Gleeson, K. Scheidhauer, C. Seidl, M. Autenrieth, F. Bruchertseifer, C. Apostolidis, F. Kurtz, T. Horn, C. Pfob, M. Schwaiger, J. Gschwend, C. D’Alessandria, A. Morgenstern, C. Uprimny, A. Kroiss, C. Decristoforo, E. von Guggenberg, B. Nilica, W. Horninger, I. Virgolini, S. Rasul, N. Poetsch, A. Woehrer, M. Preusser, M. Mitterhauser, W. Wadsak, G. Widhalm, M. Mischkulnig, M. Hacker, T. Traub-Weidinger, E. J. Wuthrick, E. D. Miller, P. Maniawski, Sebastijan Rep, Marko Hocevar, Janja Vaupotic, Urban Zdesar, Katja Zaletel, Luka Lezaic, S. Mairinger, Thomas Filip, M. Sauberer, S. Flunkert, T. Wanek, J. Stanek, N. Okamura, O. Langer, C. Kuntner, M. C. Fornito, R. Balzano, V. Di Martino, S. Cacciaguerra, G. Russo, D. Seifert, M. Kleinova, A. Cepa, J. Ralis, P. Hanc, O. Lebeda, M. Mosa, S. Vandenberghe, E. Mikhaylova, D. Borys, V. Viswanath, M. Stockhoff, N. Efthimiou, P. Caribe, R. Van Holen, J. S. Karp, P. M. Haller, C. Farhan, E. Piackova, B. Jäger, P. Knoll, A. Kiss, B. K. Podesser, J. Wojta, K. Huber, S. Mirzaei, A. Traxl, K. Komposch, Elisabeth Glitzner, M. Sibilia, M. Russello, S. Sorko, H. J. Gallowitsch, S. Kohlfuerst, S. Matschnig, M. Rieser, M. Sorschag, P. Lind, L. Ležaič, S. Rep, J. Žibert, N. Frelih, S. Šuštar, R. P. Baum, T. Langbein, A. Singh, M. Shahinfar, C. Schuchardt, G. F. Volk, H. R. Kulkarni, G. V. Di Martino, W. H. Thomson, M. Kudlacek, M. Karik, H. Rieger, W. Pokieser, K. Glaser, V. Petz, C. Tugendsam, W. Buchinger, B. Schmoll-Hauer, I. P. Schenk, K. Rudolph, M. Krebs, G. Zettinig, V. Zoufal, M. Krohn, T. Filip, J. Pahnke, F. Weitzer, B. Pernthaler, S. Salamon, R. Aigner, P. Koranda, L. Henzlová, M. Kamínek, Mo. Váchalová, P. Bachleda, D. Summer, J. Garousi, M. Oroujeni, B. Mitran, K. G. Andersson, A. Vorobyeva, J.n Löfblom, A. Orlova, V. Tolmachev, P. Kaeopookum, T. Orasch, B. Lechner, M. Petrik, Z. Novy, C. Rangger, and H. Haas

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920
Published
2018
Full Text
View/download PDF

2. FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.

Author

Malle P, Sorschag M, and Gallowitsch HJ

Subjects
Antineoplastic Agents therapeutic use, Benzamides therapeutic use, Blood Glucose metabolism, Gastrointestinal Stromal Tumors drug therapy, Humans, Imatinib Mesylate, Indoles therapeutic use, Molecular Targeted Therapy methods, Neoplasm Recurrence, Local diagnostic imaging, Piperazines therapeutic use, Prognosis, Pyrimidines therapeutic use, Pyrroles therapeutic use, Sensitivity and Specificity, Sunitinib, Treatment Outcome, Fluorodeoxyglucose F18, Gastrointestinal Stromal Tumors diagnostic imaging, Multimodal Imaging methods, Positron-Emission Tomography methods, Tomography, X-Ray Computed
Abstract

Gastrointestinal stromal tumours (GISTs) are fairly rare neoplasms, constituting less than 3 % of all gastrointestinal malignancies. The integration of molecularly targeted treatment regimes (i.e., tyrosine kinase inhibitors) in clinical oncology has revolutionized the management of patients with irresectable GISTs or metastatic disease. Malignant GISTs usually display increased glucose metabolism and therefore (18)F-fluorodeoxyglucose (FDG) uptake within the scope of positron emission tomography (PET) scans. Nowadays, dual-modality FDG PET/CT (computed tomography) imaging is of considerable value in diagnostic work-up of patients with GISTs acquiring functional and anatomic information simultaneously. The following article sheds light on the impact of FDG PET and combined FDG PET/CT imaging in initial disease evaluation, detection of tumour recurrence and the early assessment of treatment response to molecularly targeted agents such as imatinib mesylate or sunitinib maleate.

Published
2012
Full Text
View/download PDF

3. Nuclear medicine in NET.

Author

Sorschag M, Malle P, and Gallowitsch HJ

Subjects
Cell Proliferation, Dihydroxyphenylalanine analogs & derivatives, Fluorodeoxyglucose F18, Gallium Radioisotopes, Humans, Neoplasm Staging, Neuroendocrine Tumors pathology, Neuroendocrine Tumors radiotherapy, Prognosis, Biomarkers, Tumor analysis, Multimodal Imaging methods, Neuroendocrine Tumors diagnostic imaging, Positron-Emission Tomography methods, Radionuclide Imaging methods, Receptors, Peptide analysis, Receptors, Somatostatin analysis, Tomography, X-Ray Computed
Abstract

Neuroendocrine tumors (NET) are, despite increasing incidence, still rare, usually slow growing neoplasms with resemblance to nerve cells and the endocrine capability of hormone production. In contrast to commonly used conventional imaging procedures, nuclear imaging is feasible to visualize the presence of molecular biomarkers, particularly the overexpression of somatostatin receptors (sstr) with high diagnostic accuracy which has led to the establishment of somatostatin receptor scintigraphy (SRS) as essential component and gold standard of functional imaging in the workup of NET. Another major feature is the selection of patients with inoperable or metastasized tumors showing sufficient uptake for peptide receptor radionuclide therapy (PRRT). While somatostatin receptor PET and PET/CT using Ga-68-labeled SSR analogs represents the consistent further development of SRS, FDG-PET can only be used in tumors with high proliferative activity but not on a routine basis for imaging of neuroendocrine tumors. (18)F-DOPA represents an alternative PET tracer worth mentioning currently under assessment for NET imaging.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results